96
Participants
Start Date
February 28, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
Dexmedetomidine
"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
Saline placebo
An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
Royal North Shore Hospital, St Leonards
The Western Hospital, Footscray
Northern Hospital, Epping
Austin Hospital, Melbourne
The Alfred Hospital, Prahran
Toowoomba Hospital, Toowoomba
Royal Perth Hospital, Perth
Lead Sponsor
Hospira, now a wholly owned subsidiary of Pfizer
INDUSTRY
Austin Health
OTHER_GOV